SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-277887
Filing Date
2023-11-15
Accepted
2023-11-15 16:07:00
Documents
13
Period of Report
2023-11-10
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d361807d8k.htm   iXBRL 8-K 28310
2 EX-16.1 d361807dex161.htm EX-16.1 1723
  Complete submission text file 0001193125-23-277887.txt   157206

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA dawn-20231110.xsd EX-101.SCH 2858
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE dawn-20231110_lab.xml EX-101.LAB 18739
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dawn-20231110_pre.xml EX-101.PRE 11713
7 EXTRACTED XBRL INSTANCE DOCUMENT d361807d8k_htm.xml XML 3485
Mailing Address 2000 SIERRA POINT PARKWAY, SUITE 501 BRISBANE CA 94005
Business Address 2000 SIERRA POINT PARKWAY, SUITE 501 BRISBANE CA 94005 650 484-0899
Day One Biopharmaceuticals, Inc. (Filer) CIK: 0001845337 (see all company filings)

IRS No.: 832415215 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40431 | Film No.: 231410603
SIC: 2834 Pharmaceutical Preparations